thecmorgan
Member
Why do you think the sema trial was a failure? The data that was released last month looked good for the 7.2mg trial. Just wondering If I missed something.l
Sema 7.2mg and CagriSema trials both ended up being failures(hitting Novo's stock price) , despite early promising results,
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo | Applied Clinical Trials Online
Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
The randomized, double-blinded, parallel-group, superiority phase 3 STEP UP trial (ClinicalTrials.gov Identifier: NCT05646706) enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes. Study participants were randomly assigned to receive subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo once weekly; all treatments were in conjunction with lifestyle interventions.
Results based on the trial product estimand (treatment effect if all people adhered to treatment) showed semaglutide 7.2 mg-treated patients achieved a superior weight loss of 20.7% after 72 weeks compared with a weight loss of 17.5% and 2.4% in those treated with semaglutide 2.4 mg and placebo, respectively. Notably, 33.2% of patients who received semaglutide 7.2 mg had a weight loss of at least 25% compared with 16.7% with semaglutide 2.4 mg and 0.0% with placebo.
Findings from the treatment policy estimand (treatment effect regardless of treatment adherence) demonstrated similar results, with the semaglutide 7.2 mg group achieving a superior weight loss of 18.7% vs 15.6% and 3.9% for the semaglutide 2.4 mg and placebo groups, respectively.
Treatment with semaglutide 7.2mg was safe and well-tolerated, with the most common adverse events reported being mild to moderate gastrointestinal issues.
